Showing results (5491-5500 of 10,080) with videos related to
Sort By:
Pageof 1,008
Current Pharmaceutical Design|February 28, 2018
Development of an Aqueous Ophthalmic Solution with an Enhanced-Solubility Enrofloxacin Crystal, and its Clinical Evaluation in DogsJorge E Miranda-Calderon, Lilia Gutierrez, Luis Ocampo, et al.Current Pharmaceutical Design|February 28, 2018
Diabetic Foot Infection: The Role of PET/CT ImagingElite Arnon-Sheleg, Zohar KeidarCurrent Pharmaceutical Design|December 19, 2013
Attentional set-shifting in rodents: a review of behavioural methods and pharmacological resultsDavid S Tait, E Alexander Chase, Verity J BrownCurrent Pharmaceutical Design|December 19, 2013
Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophreniaDouglas L Boggs, Jon Carlson, Jose Cortes-Briones, et al.Current Pharmaceutical Design|December 19, 2013
The attentional set-shifting test paradigm in rats for the screening of novel pro-cognitive compounds with relevance for cognitive deficits in schizophreniaPascal Jean Denis Goetghebeur, Rebecca DiasCurrent Pharmaceutical Design|December 19, 2013
The novel object recognition test in rodents in relation to cognitive impairment in schizophreniaLakshmi Rajagopal, Bill W Massey, Mei Huang, et al.Current Pharmaceutical Design|November 5, 2013
Tetrahydrobiopterin regulation of eNOS redox functionDan-Dan Chen, Lu-Yuan Chen, Ji-Biao Xie, et al.Current Pharmaceutical Design|November 5, 2013
Oxidative/nitrosative stress and immuno-inflammatory pathways in depression: treatment implicationsGeorge Anderson, Michael MaesCurrent Pharmaceutical Design|November 5, 2013
Strategy for the treatment of Helicobacter pylori infectionSeiji Shiota, Yoshio YamaokaCurrent Pharmaceutical Design|November 5, 2013
Impact of antibiotics on the intestinal microbiota and on the treatment of Shiga-toxin-producing Escherichia coli and Salmonella infectionsJolanta Szych, Tomasz Wołkowicz, Roberto La Ragione, et al.Pageof 1,008